Co-Authors
This is a "connection" page, showing publications co-authored by ADEL K EL-NAGGAR and DAVID SANGHYUN HONG.
Connection Strength
0.262
-
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005.
Score: 0.095
-
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009 Nov 15; 15(22):7061-8.
Score: 0.088
-
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther. 2008 May; 7(5):1001-6.
Score: 0.079